NASDAQ:ETON Eton Pharmaceuticals (ETON) Stock Price, News & Analysis → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free ETON Stock Alerts $3.62 -0.03 (-0.82%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$3.61▼$3.7050-Day Range$3.06▼$4.5652-Week Range$2.42▼$5.81Volume25,975 shsAverage Volume53,834 shsMarket Capitalization$93.00 millionP/E Ratio90.50Dividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Eton Pharmaceuticals alerts: Email Address Eton Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside148.6% Upside$9.00 Price TargetShort InterestHealthy0.36% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.05Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.09 out of 5 starsMedical Sector357th out of 921 stocksPharmaceutical Preparations Industry163rd out of 426 stocks 3.5 Analyst's Opinion Consensus RatingEton Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEton Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Eton Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.36% of the float of Eton Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEton Pharmaceuticals has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eton Pharmaceuticals has recently decreased by 40.99%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEton Pharmaceuticals does not currently pay a dividend.Dividend GrowthEton Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ETON. Previous Next 2.3 News and Social Media Coverage News SentimentEton Pharmaceuticals has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Eton Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ETON on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows1 people have added Eton Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eton Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders13.16% of the stock of Eton Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.86% of the stock of Eton Pharmaceuticals is held by institutions.Read more about Eton Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Eton Pharmaceuticals is 90.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.82.Price to Earnings Ratio vs. SectorThe P/E ratio of Eton Pharmaceuticals is 90.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.53.Price to Book Value per Share RatioEton Pharmaceuticals has a P/B Ratio of 6.03. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eton Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaThe Overlooked Retirement Asset You Probably Don’t Own4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm.Click here to access the Crypto Retirement Blueprint now. About Eton Pharmaceuticals Stock (NASDAQ:ETON)Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Read More ETON Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ETON Stock News HeadlinesMay 12, 2024 | finance.yahoo.comEton Pharmaceuticals First Quarter 2024 Earnings: EPS Beats ExpectationsMay 12, 2024 | americanbankingnews.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Short Interest Down 41.0% in AprilMay 10, 2024 | finance.yahoo.comQ1 2024 Eton Pharmaceuticals Inc Earnings CallMay 9, 2024 | globenewswire.comEton Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 8, 2024 | markets.businessinsider.comHere's what Wall Street expects from Eton Pharmaceuticals's earnings reportMay 8, 2024 | americanbankingnews.comEton Pharmaceuticals (NASDAQ:ETON) Coverage Initiated at Craig HallumMay 7, 2024 | msn.comCraig-Hallum Initiates Coverage of Eton Pharmaceuticals (ETON) with Buy RecommendationMay 1, 2024 | globenewswire.comEton Pharmaceuticals to Present at the Citizens JMP Life Sciences ConferenceMay 1, 2024 | finance.yahoo.comPhenylketonuria (PKU) Global Clinical Trials Review 2024: Country (G7 & E7), Phase, Trial Status, End Points Status and Sponsor TypeApril 30, 2024 | markets.businessinsider.comEton Pharmaceuticals Announces NDA Submission For ET-400April 30, 2024 | globenewswire.comEton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)April 29, 2024 | globenewswire.comEton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024April 26, 2024 | msn.comPE Advent International queues up for a stake in Apollo 24/7March 22, 2024 | markets.businessinsider.comEton Pharma Buys U.S. Rights To PKU GOLIKE From Relief TherapeuticsMarch 22, 2024 | finance.yahoo.comRelief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKEMarch 22, 2024 | globenewswire.comEton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for PhenylketonuriaMarch 17, 2024 | theguardian.com‘I don’t think I developed emotionally’: Earl Spencer on the pain of boarding-school abuseMarch 17, 2024 | investing.comEarnings call: Eton Pharmaceuticals reports robust Q4 growthMarch 16, 2024 | finance.yahoo.comETON Apr 2024 5.000 callMarch 16, 2024 | seekingalpha.comEton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call TranscriptMarch 16, 2024 | benzinga.comRecap: Eton Pharmaceuticals Q4 EarningsMarch 15, 2024 | finance.yahoo.comEton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comQ4 2023 Eton Pharmaceuticals Inc Earnings CallMarch 14, 2024 | finance.yahoo.comEton Pharmaceuticals Inc (ETON) Reports Robust Sales Growth and Pipeline Progress in Q4 and ...March 14, 2024 | globenewswire.comEton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsSee More Headlines Receive ETON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eton Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/18/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ETON CUSIPN/A CIK1710340 Webwww.etonpharma.com Phone(847) 787-7361FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$10.00 Low Stock Price Target$8.00 Potential Upside/Downside+148.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.04 Trailing P/E Ratio90.50 Forward P/E RatioN/A P/E GrowthN/ANet Income$-940,000.00 Net Margins2.66% Pretax Margin3.38% Return on Equity5.65% Return on Assets2.92% Debt Debt-to-Equity RatioN/A Current Ratio1.59 Quick Ratio1.43 Sales & Book Value Annual Sales$31.64 million Price / Sales2.94 Cash Flow$0.00 per share Price / Cash Flow1,142.12 Book Value$0.60 per share Price / Book6.03Miscellaneous Outstanding Shares25,690,000Free Float22,310,000Market Cap$93.00 million OptionableOptionable Beta1.19 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Sean E. Brynjelsen (Age 52)President, CEO & Director Comp: $868.13kMr. James R. Gruber CPA (Age 52)CFO, Treasurer & Secretary Comp: $457.58kMr. David C. Krempa (Age 35)Chief Business Officer Ms. Ingrid HoosSenior Vice President of Regulatory AffairsMr. Kevin GuthrieExecutive VP of Commercial OperationsKey CompetitorsQ32 BioNASDAQ:QTTBYS BiopharmaNASDAQ:YSIO BiotechNASDAQ:IOBTProPhase LabsNASDAQ:PRPHAnnovis BioNYSE:ANVSView All CompetitorsInstitutional OwnershipAcadian Asset Management LLCBought 18,898 shares on 5/10/2024Ownership: 0.609%Westside Investment Management Inc.Bought 10,850 shares on 4/19/2024Ownership: 2.234%View All Institutional Transactions ETON Stock Analysis - Frequently Asked Questions Should I buy or sell Eton Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eton Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ETON shares. View ETON analyst ratings or view top-rated stocks. What is Eton Pharmaceuticals' stock price target for 2024? 2 brokerages have issued 12-month target prices for Eton Pharmaceuticals' shares. Their ETON share price targets range from $8.00 to $10.00. On average, they anticipate the company's share price to reach $9.00 in the next year. This suggests a possible upside of 148.6% from the stock's current price. View analysts price targets for ETON or view top-rated stocks among Wall Street analysts. How have ETON shares performed in 2024? Eton Pharmaceuticals' stock was trading at $4.38 at the beginning of 2024. Since then, ETON shares have decreased by 17.4% and is now trading at $3.62. View the best growth stocks for 2024 here. When is Eton Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ETON earnings forecast. How were Eton Pharmaceuticals' earnings last quarter? Eton Pharmaceuticals, Inc. (NASDAQ:ETON) released its earnings results on Thursday, May, 9th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.01. The company had revenue of $7.97 million for the quarter, compared to analyst estimates of $8.30 million. Eton Pharmaceuticals had a net margin of 2.66% and a trailing twelve-month return on equity of 5.65%. During the same quarter in the previous year, the company posted ($0.10) EPS. What other stocks do shareholders of Eton Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eton Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Amarin (AMRN), Myovant Sciences (MYOV), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC) and Moderna (MRNA). When did Eton Pharmaceuticals IPO? Eton Pharmaceuticals (ETON) raised $22 million in an IPO on Wednesday, November 14th 2018. The company issued 3,600,000 shares at a price of $6.00 per share. National Securities Corporation served as the underwriter for the IPO. Who are Eton Pharmaceuticals' major shareholders? Eton Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Westside Investment Management Inc. (2.23%) and Acadian Asset Management LLC (0.61%). Insiders that own company stock include Opaleye Management Inc, Pharmaceutical Co Ltd Takeda and Sean Brynjelsen. View institutional ownership trends. How do I buy shares of Eton Pharmaceuticals? Shares of ETON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ETON) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingA once-in-a-century investment opportunityStansberry ResearchMost important medical advance in 100 yearsThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
